99
100
[15] J. Liu et al., "An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics," (in eng), Cell, vol. 173, no. 2, pp. 400-416.e11, Apr 5 2018, doi:
10.1016/j.cell.2018.02.052.
[16] A. I. Nesvizhskii, A. Keller, E. Kolker, and R. Aebersold, "A statistical model for identifying proteins by tandem mass spectrometry," Analytical chemistry, vol. 75, no. 17, pp. 4646-4658, 2003.
[17] K. Sun et al., "Endotrophin triggers adipose tissue fibrosis and metabolic dysfunction," Nature communications, vol. 5, no. 1, pp. 1-12, 2014.
[18] P. Starkel and I. Leclercq, "Animal models for the study of hepatic fibrosis," Best practice &
research Clinical gastroenterology, vol. 25, no. 2, pp. 319-333, 2011.
[19] F. Heindryckx, I. Colle, and H. Van Vlierberghe, "Experimental mouse models for hepatocellular carcinoma research," International journal of experimental pathology, vol. 90, no. 4, pp. 367-386, 2009.
[20] T. Sakurai, S. Maeda, L. Chang, and M. Karin, "Loss of hepatic NF-κB activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation,"
Proceedings of the National Academy of Sciences, vol. 103, no. 28, pp. 10544-10551, 2006.
[21] V. Iansante et al., "PARP14 promotes the Warburg effect in hepatocellular carcinoma by inhibiting JNK1-dependent PKM2 phosphorylation and activation. Nat Commun 6: 7882," ed, 2015.
[22] L. Hui, K. Zatloukal, H. Scheuch, E. Stepniak, and E. F. Wagner, "Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation," The Journal of clinical investigation, vol. 118, no. 12, pp. 3943-3953, 2008.
[23] F. J. Cubero et al., "Haematopoietic cell-derived Jnk1 is crucial for chronic inflammation and carcinogenesis in an experimental model of liver injury," Journal of hepatology, vol. 62, no. 1, pp. 140-149, 2015.
[24] Q. Chang et al., "Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer," Journal of hepatology, vol. 50, no. 2, pp. 323-333, 2009.
[25] H. Malhi, M. E. Guicciardi, and G. J. Gores, "Hepatocyte death: a clear and present danger,"
Physiological reviews, vol. 90, no. 3, pp. 1165-1194, 2010.
[26] C. Garcia-Jimenez, J. M. García-Martínez, A. Chocarro-Calvo, and A. De la Vieja, "A new link between diabetes and cancer: enhanced WNT/β-catenin signaling by high glucose," Journal of molecular endocrinology, vol. 52, no. 1, pp. R51-R66, 2014.
[27] A. Vasconcelos-Dos-Santos et al., "Hyperglycemia exacerbates colon cancer malignancy through hexosamine biosynthetic pathway," Oncogenesis, vol. 6, no. 3, pp. e306-e306, 2017.
[28] J. C. Montero, R. Rodríguez-Barrueco, A. Ocaña, E. Díaz-Rodríguez, A. Esparís-Ogando, and
101
A. Pandiella, "Neuregulins and cancer," Clinical cancer research, vol. 14, no. 11, pp. 3237- 3241, 2008.
[29] Y. Chua et al., "The NRG1 gene is frequently silenced by methylation in breast cancers and is a strong candidate for the 8p tumour suppressor gene," Oncogene, vol. 28, no. 46, pp. 4041- 4052, 2009.
[30] C. Minning et al., "Exploring breast carcinogenesis through integrative genomics and epigenomics analyses," Int J Oncol, vol. 45, no. 5, pp. 1959-1968, 2014/11/01 2014, doi:
10.3892/ijo.2014.2625.
[31] M. B. Stadler et al., "DNA-binding factors shape the mouse methylome at distal regulatory regions," Nature, vol. 480, no. 7378, pp. 490-495, 2011.
[32] M. L. Jin et al., "Aberrant expression of SETD1A promotes survival and migration of estrogen receptor α‐positive breast cancer cells," International journal of cancer, vol. 143, no. 11, pp.
2871-2883, 2018.
[33] L. Wang et al., "A cytoplasmic COMPASS is necessary for cell survival and triple-negative breast cancer pathogenesis by regulating metabolism," Genes & development, vol. 31, no. 20, pp. 2056-2066, 2017.
[34] T. Borggrefe and F. Oswald, "Setting the stage for Notch: the Drosophila Su (H)-hairless repressor complex," PLoS biology, vol. 14, no. 7, p. e1002524, 2016.
[35] F. Oswald et al., "RBP-Jκ/SHARP recruits CtIP/CtBP corepressors to silence Notch target genes," Molecular and cellular biology, vol. 25, no. 23, pp. 10379-10390, 2005.
[36] K. Tanigaki and T. Honjo, "Two opposing roles of RBP-J in Notch signaling," (in eng), Current topics in developmental biology, vol. 92, pp. 231-52, 2010, doi: 10.1016/s0070-2153(10)92007- 3.
[37] O. Fornes et al., "JASPAR 2020: update of the open-access database of transcription factor binding profiles," Nucleic acids research, vol. 48, no. D1, pp. D87-D92, 2020.
[38] L. Yang et al., "NRG1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells," International Journal of Oncology, vol. 51, no.
5, pp. 1553-1562, 2017.
[39] K. Pandya et al., "Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence," British Journal of Cancer, vol. 105, no. 6, pp. 796-806, 2011/09/01 2011, doi: 10.1038/bjc.2011.321.
[40] G. D. Girnun et al., "Synergy between PPARγ ligands and platinum-based drugs in cancer,"
Cancer cell, vol. 11, no. 5, pp. 395-406, 2007.
[41] J. Park, T. S. Morley, and P. E. Scherer, "Inhibition of endotrophin, a cleavage product of collagen VI, confers cisplatin sensitivity to tumours," EMBO molecular medicine, vol. 5, no. 6,
102 pp. 935-948, 2013.
[42] C. Blanquicett, J. Roman, and C. M. Hart, "Thiazolidinediones as anti-cancer agents," Cancer therapy, vol. 6, no. A, p. 25, 2008.
[43] J. Huang, H. Li, and G. Ren, "Epithelial-mesenchymal transition and drug resistance in breast cancer," International journal of oncology, vol. 47, no. 3, pp. 840-848, 2015.
[44] S. Baribeau, P. Chaudhry, S. Parent, and É. Asselin, "Resveratrol inhibits cisplatin-induced epithelial-to-mesenchymal transition in ovarian cancer cell lines," PLoS One, vol. 9, no. 1, p.
e86987, 2014.
[45] J. M. Buonato and M. J. Lazzara, "ERK1/2 Blockade Prevents Epithelial–Mesenchymal Transition in Lung Cancer Cells and Promotes Their Sensitivity to EGFR InhibitionERK Inhibition Prevents EMT in Lung Cancer Cells," Cancer research, vol. 74, no. 1, pp. 309-319, 2014.
[46] I. C. Salaroglio, E. Mungo, E. Gazzano, J. Kopecka, and C. Riganti, "ERK is a pivotal player of chemo-immune-resistance in cancer," International journal of molecular sciences, vol. 20, no. 10, p. 2505, 2019.
[47] K. K. Lai et al., "Extracellular matrix dynamics in hepatocarcinogenesis: a comparative proteomics study of PDGFC transgenic and Pten null mouse models," PLoS genetics, vol. 7, no. 6, p. e1002147, 2011.
[48] Y. Hoshida et al., "Gene expression in fixed tissues and outcome in hepatocellular carcinoma,"
New England Journal of Medicine, vol. 359, no. 19, pp. 1995-2004, 2008.
[49] S. Faouzi et al., "Myofibroblasts are responsible for collagen synthesis in the stroma of human hepatocellular carcinoma: an in vivo and in vitro study," Journal of hepatology, vol. 30, no. 2, pp. 275-284, 1999.
[50] S. Stanley, A. Moheet, and E. R. Seaquist, "Central mechanisms of glucose sensing and counterregulation in defense of hypoglycemia," Endocrine reviews, vol. 40, no. 3, pp. 768-788, 2019.
[51] T. Issad and M. Kuo, "O-GlcNAc modification of transcription factors, glucose sensing and glucotoxicity," Trends in Endocrinology & Metabolism, vol. 19, no. 10, pp. 380-389, 2008.
[52] J. Bricambert, J. Miranda, F. Benhamed, J. Girard, C. Postic, and R. Dentin, "Salt-inducible kinase 2 links transcriptional coactivator p300 phosphorylation to the prevention of ChREBP- dependent hepatic steatosis in mice," The Journal of clinical investigation, vol. 120, no. 12, pp.
4316-4331, 2010.
[53] H. Cha-Molstad, G. Saxena, J. Chen, and A. Shalev, "Glucose-stimulated expression of Txnip is mediated by carbohydrate response element-binding protein, p300, and histone H4 acetylation in pancreatic beta cells," Journal of Biological Chemistry, vol. 284, no. 25, pp.
103 16898-16905, 2009.
[54] S. Katada, A. Imhof, and P. Sassone-Corsi, "Connecting threads: epigenetics and metabolism,"
Cell, vol. 148, no. 1-2, pp. 24-28, 2012.
[55] J. V. Lee et al., "Akt-dependent metabolic reprogramming regulates tumor cell histone acetylation," Cell metabolism, vol. 20, no. 2, pp. 306-319, 2014.
[56] K. E. Wellen, G. Hatzivassiliou, U. M. Sachdeva, T. V. Bui, J. R. Cross, and C. B. Thompson,
"ATP-citrate lyase links cellular metabolism to histone acetylation," (in eng), Science, vol. 324, no. 5930, pp. 1076-80, May 22 2009, doi: 10.1126/science.1164097.
[57] A. Krejčí and S. Bray, "Notch activation stimulates transient and selective binding of Su (H)/CSL to target enhancers," Genes & development, vol. 21, no. 11, pp. 1322-1327, 2007.
[58] D. Castel, P. Mourikis, S. J. Bartels, A. B. Brinkman, S. Tajbakhsh, and H. G. Stunnenberg,
"Dynamic binding of RBPJ is determined by Notch signaling status," Genes & development, vol. 27, no. 9, pp. 1059-1071, 2013.
[59] H. Wang et al., "NOTCH1–RBPJ complexes drive target gene expression through dynamic interactions with superenhancers," Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 2, pp. 705-710, 2014.
[60] D. Shah et al., "Inhibition of HER2 increases JAGGED1-dependent breast cancer stem cells:
Role for membrane JAGGED1," Clinical Cancer Research, vol. 24, no. 18, pp. 4566-4578, 2018.
[61] A. Sonnenblick et al., "Impact of diabetes, insulin, and metformin use on the outcome of patients with human epidermal growth factor receptor 2–positive primary breast cancer:
analysis from the ALTTO Phase III randomized trial," Journal of Clinical Oncology, vol. 35, no. 13, p. 1421, 2017.
[62] A. Lee et al., "Diabetes as a prognostic factor in HER-2 positive breast cancer patients treated with targeted therapy," Breast Cancer, vol. 26, no. 5, pp. 672-680, 2019.
[63] D. L. Abravanel et al., "Notch promotes recurrence of dormant tumor cells following HER2/neu-targeted therapy," The Journal of clinical investigation, vol. 125, no. 6, pp. 2484- 2496, 2015.
[64] P. Rizzo, C. Osipo, K. Foreman, T. Golde, B. Osborne, and L. Miele, "Rational targeting of Notch signaling in cancer," Oncogene, vol. 27, no. 38, pp. 5124-5131, 2008.
[65] I. Espinoza and L. Miele, "Notch inhibitors for cancer treatment," Pharmacology &
therapeutics, vol. 139, no. 2, pp. 95-110, 2013.
[66] B. Zhou et al., "Notch signaling pathway: Architecture, disease, and therapeutics," Signal transduction and targeted therapy, vol. 7, no. 1, pp. 1-33, 2022.
[67] K. Miloudi et al., "NOTCH1 signaling induces pathological vascular permeability in diabetic
104
retinopathy," Proceedings of the National Academy of Sciences of the United States of America, vol. 116, no. 10, pp. 4538-4547, 2019.
[68] T. Niranjan et al., "The Notch pathway in podocytes plays a role in the development of glomerular disease," Nature medicine, vol. 14, no. 3, pp. 290-298, 2008.
[69] L. J. Schwarz et al., "An ERBB1-3 neutralizing antibody mixture with high activity against drug-resistant HER2+ breast cancers with ERBB ligand overexpression," JNCI: Journal of the National Cancer Institute, vol. 109, no. 11, p. djx065, 2017.
[70] L. D. Mayer and A. S. Janoff, "Optimizing combination chemotherapy by controlling drug ratios," Molecular interventions, vol. 7, no. 4, p. 216, 2007.
[71] J. Zhang et al., "Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer," International journal of cancer, vol. 136, no. 1, pp. 204-211, 2015.
[72] M. Vassilomanolakis et al., "First-line chemotherapy with docetaxel and cisplatin in metastatic breast cancer," The Breast, vol. 14, no. 2, pp. 136-141, 2005.
[73] W. Song et al., "Polypeptide-based combination of paclitaxel and cisplatin for enhanced chemotherapy efficacy and reduced side-effects," Acta Biomaterialia, vol. 10, no. 3, pp. 1392- 1402, 2014.
[74] H. K. Chew, "Adjuvant therapy for breast cancer: who should get what?," Western Journal of medicine, vol. 174, no. 4, p. 284, 2001.
[75] F. Qi et al., "Chinese herbal medicines as adjuvant treatment during chemoor radio-therapy for cancer," Bioscience trends, vol. 4, no. 6, 2010.
[76] T. N. Aung, Z. Qu, R. D. Kortschak, and D. L. Adelson, "Understanding the effectiveness of natural compound mixtures in cancer through their molecular mode of action," International journal of molecular sciences, vol. 18, no. 3, p. 656, 2017.
[77] R. J. Davis, "Signal transduction by the JNK group of MAP kinases," Inflammatory Processes:, pp. 13-21, 2000.
[78] E. Seki, D. A. Brenner, and M. Karin, "A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches," Gastroenterology, vol. 143, no. 2, pp. 307-320, 2012.
[79] E. F. Wagner and Á. R. Nebreda, "Signal integration by JNK and p38 MAPK pathways in cancer development," Nature Reviews Cancer, vol. 9, no. 8, pp. 537-549, 2009.
[80] K. Zhang et al., "A Notch1–neuregulin1 autocrine signaling loop contributes to melanoma growth," Oncogene, vol. 31, no. 43, pp. 4609-4618, 2012.
[81] J. Grego-Bessa et al., "Notch signaling is essential for ventricular chamber development,"
Developmental cell, vol. 12, no. 3, pp. 415-429, 2007.
[82] A. Gandalovičová et al., "Migrastatics—anti-metastatic and anti-invasion drugs: promises and
105
challenges," Trends in cancer, vol. 3, no. 6, pp. 391-406, 2017.
[83] T. Zhang et al., "Cucurbitacin E inhibits breast tumor metastasis by suppressing cell migration and invasion," Breast cancer research and treatment, vol. 135, no. 2, pp. 445-458, 2012.
[84] W. Zhao et al., "Candidate Antimetastasis Drugs Suppress the Metastatic Capacity of Breast Cancer Cells by Reducing Membrane FluidityMembrane Fluidity Controls Metastasis," Cancer research, vol. 76, no. 7, pp. 2037-2049, 2016.
[85] J. T. Thaiparambil et al., "Withaferin A inhibits breast cancer invasion and metastasis at sub‐
cytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation,"
International journal of cancer, vol. 129, no. 11, pp. 2744-2755, 2011.
[86] A. Bardia et al., "Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer," New England Journal of Medicine, vol. 380, no. 8, pp. 741-751, 2019.
106